ADPT President and COO Julie Rubinstein Sells $291K of Stock
Key Points
- Adaptive Biotechnologies Corporation president and COO Julie Rubinstein sold 11,881 shares of stock on October 20, 2026, for about $291,473 under a planned trading schedule.
- After the trade, Julie Rubinstein holds 377,802 $ADPT shares, down 3.05% from before the trade.
- The company reported trailing-twelve-month revenue of $308.1 million alongside an EPS loss of $0.41, with its next earnings report scheduled for November 4, 2026.
- Major institutions like Viking Global Investors, D.E. Shaw, and Westfield Capital recently adjusted their stakes in the diagnostics firm.
Since the trade, $ADPT is up 3.7% to date (from the $24.42 close on Oct 20, 2026).
Get Adaptive Biotechnologies text alerts
We text you when insiders, Congress, analysts or big funds move on $ADPT.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Adaptive Biotechnologies Corporation alert may contain errors. Disclosures
Adaptive Biotechnologies Corporation president and COO Julie Rubinstein sold 11,881 shares of the company's stock on October 20, 2026. The transaction was revealed in a Form 4 filing with the Securities and Exchange Commission. The shares were sold at an average price of $24.53 per share, bringing the total value of the sale to about $291,473.
ADPT
Adaptive Biotechnologies Corporation
Inside Julie Rubinstein's ADPT Trade
The sale took place under a pre-arranged trading plan. Following the transaction, Rubinstein directly held 377,802 shares of Adaptive Biotechnologies Corporation. This transaction marked a 3.05% reduction in her holdings. The stock closed at $24.42 on the day of the trade.
Other Institutional Activity in Adaptive Biotechnologies Corporation
Other large funds have also adjusted their positions in the company recently. Viking Global Investors, L.P. kept its stake steady at 29,993,708 shares valued at about $759.7 million. Shaw D.E. & Co., Inc. grew its holdings by 2,660,252 shares, ending with 4,625,859 shares worth about $117.2 million after a 135.3% increase. Westfield Capital Management Co LP reduced its position by 1,168,845 shares, ending with 4,267,645 shares worth about $108.1 million following a 21.5% decrease.
Adaptive Biotechnologies Corporation Stock Holds Steady
The stock recently traded around $24.42 as of October 21, 2026, putting it about 20.6% below its 52-week high of $30.74 and well above its 52-week low of $12.00. The shares trade 6.6% below their 50-day moving average of $26.13 and 27.1% above their 200-day moving average of $19.22.
Recent Earnings
Adaptive Biotechnologies Corporation reported trailing-twelve-month revenue of $308,080,992 with an EPS of -$0.41. The firm posted a year-over-year revenue growth rate of 21.5%, alongside a net profit margin of -20.7% and a return on equity of -38.8%. The company's next earnings report is scheduled for November 4, 2026.
Insider Buying and Selling at Adaptive Biotechnologies Corporation
Rubinstein executed four earlier planned sales between October 13 and October 16, 2026, each for 11,881 shares.
Analysts Set New Price Targets
Wall Street analysts maintain a strong buy consensus on the stock with a mean price target of $29.81 across eight opinions.
About Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation operates as a commercial-stage enterprise that builds an immune medicine platform focused on diagnosing and treating various diseases. The firm utilizes a proprietary immunosequencing platform that combines chemistry, computational biology, and machine learning to interpret clinical immunomics data and decode the adaptive immune system.
Bottom Line
Investors will watch the upcoming earnings report on November 4, 2026, for further financial updates. Future filings will show whether company executives continue trimming their holdings under planned schedules.
Related Filing Alerts
Source: Julie Rubinstein's Form 4 filing on $ADPT (Oct 20, 2026). Written by software, not financial advice. How we make alerts